{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:22:27Z","timestamp":1793424147022,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T00:00:00Z","timestamp":1592611200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T00:00:00Z","timestamp":1592611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Folkh\u00e4lsan Research Foundation, Academy of Finland","award":["316664"],"award-info":[{"award-number":["316664"]}]},{"DOI":"10.13039\/100010113","name":"Wilhelm och Else Stockmanns Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010113","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Liv och H\u00e4lsa Society"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Aims\/hypothesis<\/jats:title>\n<jats:p>Lipid abnormalities are associated with diabetic kidney disease and CHD, although their exact role has not yet been fully explained. Sphingomyelin, the predominant sphingolipid in humans, is crucial for intact glomerular and endothelial function. Therefore, the objective of our study was to investigate whether sphingomyelin impacts kidney disease and CHD progression in individuals with type 1 diabetes.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Individuals (<jats:italic>n<\/jats:italic>\u2009=\u20091087) from the Finnish Diabetic Nephropathy (FinnDiane) prospective cohort study with serum sphingomyelin measured using a proton NMR metabolomics platform were included. Kidney disease progression was defined as change in eGFR or albuminuria stratum. Data on incident end-stage renal disease (ESRD) and CHD were retrieved from national registries. HRs from Cox regression models and regression coefficients from the logistic or linear regression analyses were reported per 1 SD increase in sphingomyelin level. In addition, receiver operating curves were used to assess whether sphingomyelin improves eGFR decline prediction compared with albuminuria.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>During a median (IQR) 10.7 (6.4, 13.5) years of follow-up, sphingomyelin was independently associated with the fastest eGFR decline (lowest 25%; median [IQR] for eGFR change: &lt;\u22124.4 [\u22126.8, \u22123.1] ml min<jats:sup>\u22121<\/jats:sup> [1.73\u00a0m<jats:sup>\u22122<\/jats:sup>] year<jats:sup>\u22121<\/jats:sup>), even after adjustment for classical lipid variables such as HDL-cholesterol and triacylglycerols (OR [95% CI]: 1.36 [1.15, 1.61], <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Similarly, sphingomyelin increased the risk of progression to ESRD (HR [95% CI]: 1.53 [1.19, 1.97], <jats:italic>p<\/jats:italic>\u2009=\u20090.001). Moreover, sphingomyelin increased the risk of CHD (HR [95% CI]: 1.24 [1.01, 1.52], <jats:italic>p<\/jats:italic>\u2009=\u20090.038). However, sphingomyelin did not perform better than albuminuria in the prediction of eGFR decline.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions\/interpretation<\/jats:title>\n<jats:p>This study demonstrates for the first time in a prospective setting that sphingomyelin is associated with the fastest eGFR decline and progression to ESRD in type 1 diabetes. In addition, sphingomyelin is a risk factor for CHD. These data suggest that high sphingomyelin level, independently of classical lipid risk factors, may contribute not only to the initiation and progression of kidney disease but also to CHD.<\/jats:p>\n\n<\/jats:sec>","DOI":"10.1007\/s00125-020-05201-9","type":"journal-article","created":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T11:02:58Z","timestamp":1592650978000},"page":"1847-1856","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Sphingomyelin and progression of renal and coronary heart disease in individuals with type 1 diabetes"],"prefix":"10.1007","volume":"63","author":[{"given":"Drazenka","family":"Pongrac Barlovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valma","family":"Harjutsalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niina","family":"Sandholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Forsblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4055-6954","authenticated-orcid":false,"given":"Per-Henrik","family":"Groop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the FinnDiane Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,20]]},"reference":[{"key":"5201_CR1","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.2337\/db08-1543","volume":"58","author":"PH Groop","year":"2009","unstructured":"Groop PH, Thomas MC, Moran JL et al (2009) The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes 58:1651\u20131658","journal-title":"Diabetes"},{"issue":"Suppl 3","key":"5201_CR2","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.2337\/diabetes.53.suppl_3.S39","volume":"53","author":"P Gaede","year":"2004","unstructured":"Gaede P, Pedersen O (2004) Intensive integrated therapy of type 2 diabetes: Implications for long-term prognosis. Diabetes 53(Suppl 3):S39\u2013S47","journal-title":"Diabetes"},{"key":"5201_CR3","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.2337\/dc13-2873","volume":"37","author":"N Tolonen","year":"2014","unstructured":"Tolonen N, Forsblom C, Makinen VP et al (2014) Different lipid variables predict incident coronary artery disease in patients with type 1 diabetes with or without diabetic nephropathy: The FinnDiane study. Diabetes Care 37:2374\u20132382","journal-title":"Diabetes Care"},{"key":"5201_CR4","doi-asserted-by":"crossref","unstructured":"Palmer SC, Navaneethan SD, Craig JC et al (2014) HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev Issue 2, Art. no.: Cd007784","DOI":"10.1002\/14651858.CD007784.pub2"},{"key":"5201_CR5","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.plipres.2013.05.001","volume":"52","author":"JP Slotte","year":"2013","unstructured":"Slotte JP (2013) Biological functions of sphingomyelins. Prog Lipid Res 52:424\u2013437","journal-title":"Prog Lipid Res"},{"issue":"1","key":"5201_CR6","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1038\/s41467-019-10584-4","volume":"10","author":"A Mitrofanova","year":"2019","unstructured":"Mitrofanova A, Mallela SK, Ducasa GM et al (2019) SMPDL3b modulates insulin receptor signaling in diabetic kidney disease. Nat Commun 10(1):2692","journal-title":"Nat Commun"},{"issue":"6","key":"5201_CR7","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1161\/ATVBAHA.116.305675","volume":"36","author":"A Edsfeldt","year":"2016","unstructured":"Edsfeldt A, Dun\u00e9r P, St\u00e5hlman M et al (2016) Sphingolipids contribute to human atherosclerotic plaque inflammation. Arterioscler Thromb Vasc Biol 36(6):1132\u20131140","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"5201_CR8","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s11306-011-0343-y","volume":"8","author":"VP Makinen","year":"2012","unstructured":"Makinen VP, Tynkkynen T, Soininen P et al (2012) Sphingomyelin is associated with kidney disease in type 1 diabetes (the FinnDiane Study). Metabolomics 8:369\u2013375","journal-title":"Metabolomics"},{"key":"5201_CR9","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.metabol.2014.07.001","volume":"63","author":"RL Klein","year":"2014","unstructured":"Klein RL, Hammad SM, Baker NL et al (2014) Decreased plasma levels of select very long chain ceramide species are associated with the development of nephropathy in type 1 diabetes. Metabolism 63:1287\u20131295","journal-title":"Metabolism"},{"key":"5201_CR10","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1161\/CIRCULATIONAHA.116.024261","volume":"135","author":"DD Wang","year":"2017","unstructured":"Wang DD, Toledo E, Hruby A et al (2017) Plasma ceramides, Mediterranean diet, and incident cardiovascular disease in the PREDIMED trial (Prevencion con Dieta Mediterranea). Circulation 135:2028\u20132040","journal-title":"Circulation"},{"key":"5201_CR11","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1093\/eurheartj\/ehw148","volume":"37","author":"R Laaksonen","year":"2016","unstructured":"Laaksonen R, Ekroos K, Sysi-Aho M et al (2016) Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol. Eur Heart J 37:1967\u20131976","journal-title":"Eur Heart J"},{"key":"5201_CR12","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1161\/ATVBAHA.109.199281","volume":"30","author":"J Yeboah","year":"2010","unstructured":"Yeboah J, McNamara C, Jiang XC et al (2010) Association of plasma sphingomyelin levels and incident coronary heart disease events in an adult population: Multi-Ethnic Study of Atherosclerosis. Arterioscler Thromb Vasc Biol 30:628\u2013633","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"5201_CR13","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1021\/pr201036j","volume":"11","author":"VP Makinen","year":"2012","unstructured":"Makinen VP, Tynkkynen T, Soininen P et al (2012) Metabolic diversity of progressive kidney disease in 325 patients with type 1 diabetes (the FinnDiane Study). J Proteome Res 11:1782\u20131790","journal-title":"J Proteome Res"},{"key":"5201_CR14","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.2337\/db08-0332","volume":"57","author":"VP Makinen","year":"2008","unstructured":"Makinen VP, Forsblom C, Thorn LM et al (2008) Metabolic phenotypes, vascular complications, and premature deaths in a population of 4,197 patients with type 1 diabetes. Diabetes 57:2480\u20132487","journal-title":"Diabetes"},{"key":"5201_CR15","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604\u2013612","journal-title":"Ann Intern Med"},{"issue":"11","key":"5201_CR16","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1007\/s00125-019-4948-4","volume":"62","author":"M Oshima","year":"2019","unstructured":"Oshima M, Jun M, Ohkuma T et al (2019) The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study. Diabetologia 62(11):1988\u20131997","journal-title":"Diabetologia"},{"issue":"2","key":"5201_CR17","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1053\/j.ajkd.2013.08.028","volume":"63","author":"W Yang","year":"2014","unstructured":"Yang W, Xie D, Anderson A et al (2014) Association of kidney disease outcomes with risk factors for CKD: findings from the Chronic Renal Insufficiency Cohort (CRIC) study. Am J Kidney Dis 63(2):236\u2013243","journal-title":"Am J Kidney Dis"},{"key":"5201_CR18","volume-title":"Generalized additive models","author":"TJ Hastie","year":"1990","unstructured":"Hastie TJ, Tibshirani RJ (1990) Generalized additive models. Chapman & Hall, Boca Raton, Florida"},{"key":"5201_CR19","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nrendo.2016.169","volume":"13","author":"PJ Meikle","year":"2017","unstructured":"Meikle PJ, Summers SA (2017) Sphingolipids and phospholipids in insulin resistance and related metabolic disorders. Nat Rev Endocrinol 13:79\u201391","journal-title":"Nat Rev Endocrinol"},{"key":"5201_CR20","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1681\/ASN.2013111213","volume":"26","author":"TH Yoo","year":"2015","unstructured":"Yoo TH, Pedigo CE, Guzman J et al (2015) Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease. J Am Soc Nephrol 26:133\u2013147","journal-title":"J Am Soc Nephrol"},{"key":"5201_CR21","doi-asserted-by":"crossref","first-page":"F204","DOI":"10.1152\/ajprenal.00150.2015","volume":"309","author":"M Subathra","year":"2015","unstructured":"Subathra M, Korrapati M, Howell LA et al (2015) Kidney glycosphingolipids are elevated early in diabetic nephropathy and mediate hypertrophy of mesangial cells. Am J Physiol Renal Physiol 309:F204\u2013F215","journal-title":"Am J Physiol Renal Physiol"},{"issue":"3","key":"5201_CR22","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.ekir.2016.12.003","volume":"2","author":"JJ Liu","year":"2017","unstructured":"Liu JJ, Ghosh S, Kovalik JP et al (2017) Profiling of plasma metabolites suggests altered mitochondrial fuel usage and remodeling of sphingolipid metabolism in individuals with type 2 diabetes and kidney disease. Kidney Int Rep 2(3):470\u2013480","journal-title":"Kidney Int Rep"},{"key":"5201_CR23","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/joim.12026","volume":"273","author":"VP Makinen","year":"2013","unstructured":"Makinen VP, Soininen P, Kangas AJ et al (2013) Triglyceride-cholesterol imbalance across lipoprotein subclasses predicts diabetic kidney disease and mortality in type 1 diabetes: the FinnDiane Study. J Intern Med 273:383\u2013395","journal-title":"J Intern Med"},{"key":"5201_CR24","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1388-1981(00)00071-8","volume":"1486","author":"H Saito","year":"2000","unstructured":"Saito H, Arimoto I, Tanaka M et al (2000) Inhibition of lipoprotein lipase activity by sphingomyelin: role of membrane surface structure. Biochim Biophys Acta 1486:312\u2013320","journal-title":"Biochim Biophys Acta"},{"key":"5201_CR25","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/MCA.0000000000000079","volume":"25","author":"W Pan","year":"2014","unstructured":"Pan W, Yu J, Shi R et al (2014) Elevation of ceramide and activation of secretory acid sphingomyelinase in patients with acute coronary syndromes. Coron Artery Dis 25:230\u2013235","journal-title":"Coron Artery Dis"},{"issue":"1","key":"5201_CR26","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrneph.2017.155","volume":"14","author":"S Agrawal","year":"2018","unstructured":"Agrawal S, Zaritsky JJ, Fornoni A, Smoyer WE (2018) Dyslipidaemia in nephrotic syndrome: mechanisms and treatment. Nat Rev Nephrol 14(1):57\u201370","journal-title":"Nat Rev Nephrol"},{"issue":"12","key":"5201_CR27","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s11892-019-1263-x","volume":"19","author":"GM Ducasa","year":"2019","unstructured":"Ducasa GM, Mitrofanova A, Fornoni A (2019) Crosstalk between lipids and mitochondria in diabetic kidney disease. Curr Diab Rep 19(12):144","journal-title":"Curr Diab Rep"},{"key":"5201_CR28","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1172\/JCI870","volume":"101","author":"T Jeong","year":"1998","unstructured":"Jeong T, Schissel SL, Tabas I, Pownall HJ, Tall AR, Jiang X (1998) Increased sphingomyelin content of plasma lipoproteins in apolipoprotein E knockout mice reflects combined production and catabolic defects and enhances reactivity with mammalian sphingomyelinase. J Clin Invest 101:905\u2013912","journal-title":"J Clin Invest"},{"key":"5201_CR29","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.diabres.2011.03.017","volume":"93","author":"L Chun","year":"2011","unstructured":"Chun L, Junlin Z, Aimin W, Niansheng L, Benmei C, Minxiang L (2011) Inhibition of ceramide synthesis reverses endothelial dysfunction and atherosclerosis in streptozotocin-induced diabetic rats. Diabetes Res Clin Pract 93:77\u201385","journal-title":"Diabetes Res Clin Pract"},{"key":"5201_CR30","doi-asserted-by":"crossref","first-page":"10284","DOI":"10.1074\/jbc.M412348200","volume":"280","author":"MR Hojjati","year":"2005","unstructured":"Hojjati MR, Li Z, Zhou H et al (2005) Effect of myriocin on plasma sphingolipid metabolism and atherosclerosis in apoE-deficient mice. J Biol Chem 280:10284\u201310289","journal-title":"J Biol Chem"},{"key":"5201_CR31","doi-asserted-by":"crossref","first-page":"E398","DOI":"10.1152\/ajpendo.00134.2015","volume":"309","author":"BC Bergman","year":"2015","unstructured":"Bergman BC, Brozinick JT, Strauss A et al (2015) Serum sphingolipids: relationships to insulin sensitivity and changes with exercise in humans. Am J Physiol Endocrinol Metab 309:E398\u2013E408","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"5201_CR32","doi-asserted-by":"crossref","first-page":"24202","DOI":"10.1074\/jbc.274.34.24202","volume":"274","author":"C Schmitz-Peiffer","year":"1999","unstructured":"Schmitz-Peiffer C, Craig DL, Biden TJ (1999) Ceramide generation is sufficient to account for the inhibition of the insulin-stimulated PKB pathway in C2C12 skeletal muscle cells pretreated with palmitate. J Biol Chem 274:24202\u201324210","journal-title":"J Biol Chem"},{"key":"5201_CR33","doi-asserted-by":"crossref","first-page":"5457","DOI":"10.1128\/MCB.18.9.5457","volume":"18","author":"SA Summers","year":"1998","unstructured":"Summers SA, Garza LA, Zhou H, Birnbaum MJ (1998) Regulation of insulin-stimulated glucose transporter GLUT4 translocation and Akt kinase activity by ceramide. Mol Cell Biol 18:5457\u20135464","journal-title":"Mol Cell Biol"},{"key":"5201_CR34","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.cmet.2011.07.015","volume":"14","author":"KE Bornfeldt","year":"2011","unstructured":"Bornfeldt KE, Tabas I (2011) Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab 14:575\u2013585","journal-title":"Cell Metab"},{"key":"5201_CR35","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/ncpendmet0046","volume":"1","author":"PH Groop","year":"2005","unstructured":"Groop PH, Forsblom C, Thomas MC (2005) Mechanisms of disease: pathway-selective insulin resistance and microvascular complications of diabetes. Nat Clin Pract Endocrinol Metab 1:100\u2013110","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"5201_CR36","doi-asserted-by":"crossref","first-page":"16901","DOI":"10.1074\/jbc.274.24.16901","volume":"274","author":"JY Lehtonen","year":"1999","unstructured":"Lehtonen JY, Horiuchi M, Daviet L, Akishita M, Dzau VJ (1999) Activation of the de novo biosynthesis of sphingolipids mediates angiotensin II type 2 receptor-induced apoptosis. J Biol Chem 274:16901\u201316906","journal-title":"J Biol Chem"},{"key":"5201_CR37","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1161\/01.RES.0000253900.66640.34","volume":"100","author":"D Pchejetski","year":"2007","unstructured":"Pchejetski D, Kunduzova O, Dayon A et al (2007) Oxidative stress-dependent sphingosine kinase-1 inhibition mediates monoamine oxidase A-associated cardiac cell apoptosis. Circ Res 100:41\u201349","journal-title":"Circ Res"},{"key":"5201_CR38","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/414813a","volume":"414","author":"M Brownlee","year":"2001","unstructured":"Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813\u2013820","journal-title":"Nature"},{"key":"5201_CR39","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1161\/01.CIR.0000035650.05921.50","volume":"106","author":"H Li","year":"2002","unstructured":"Li H, Junk P, Huwiler A et al (2002) Dual effect of ceramide on human endothelial cells: induction of oxidative stress and transcriptional upregulation of endothelial nitric oxide synthase. Circulation 106:2250\u20132256","journal-title":"Circulation"},{"key":"5201_CR40","doi-asserted-by":"crossref","unstructured":"Demirkan A, van Duijn CM, Ugocsai P et al (2012) Genome-wide association study identifies novel loci associated with circulating phospho- and sphingolipid concentrations. PLoS Genet 8:e1002490","DOI":"10.1371\/journal.pgen.1002490"},{"key":"5201_CR41","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1161\/01.ATV.18.10.1523","volume":"18","author":"S Chatterjee","year":"1998","unstructured":"Chatterjee S (1998) Sphingolipids in atherosclerosis and vascular biology. Arterioscler Thromb Vasc Biol 18:1523\u20131533","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"5201_CR42","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s00125-015-3850-y","volume":"59","author":"BC Bergman","year":"2016","unstructured":"Bergman BC, Brozinick JT, Strauss A et al (2016) Muscle sphingolipids during rest and exercise: a C18:0 signature for insulin resistance in humans. Diabetologia 59:785\u2013798","journal-title":"Diabetologia"},{"key":"5201_CR43","doi-asserted-by":"crossref","first-page":"E2335","DOI":"10.1210\/jc.2014-1665","volume":"99","author":"TW Ng","year":"2014","unstructured":"Ng TW, Ooi EM, Watts GF et al (2014) Dose-dependent effects of rosuvastatin on the plasma sphingolipidome and phospholipidome in the metabolic syndrome. J Clin Endocrinol Metab 99:E2335\u2013E2340","journal-title":"J Clin Endocrinol Metab"},{"key":"5201_CR44","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jacl.2015.03.011","volume":"9","author":"A Othman","year":"2015","unstructured":"Othman A, Benghozi R, Alecu I et al (2015) Fenofibrate lowers atypical sphingolipids in plasma of dyslipidemic patients: a novel approach for treating diabetic neuropathy? J Clin Lipidol 9:568\u2013575","journal-title":"J Clin Lipidol"},{"key":"5201_CR45","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.atherosclerosis.2013.03.029","volume":"228","author":"MT Janis","year":"2013","unstructured":"Janis MT, Tarasov K, Ta HX et al (2013) Beyond LDL-C lowering: distinct molecular sphingolipids are good indicators of proprotein convertase subtilisin\/kexin type 9 (PCSK9) deficiency. Atherosclerosis 228:380\u2013385","journal-title":"Atherosclerosis"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-020-05201-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-020-05201-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-020-05201-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,19]],"date-time":"2021-06-19T23:07:20Z","timestamp":1624144040000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-020-05201-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,20]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["5201"],"URL":"https:\/\/doi.org\/10.1007\/s00125-020-05201-9","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,20]]},"assertion":[{"value":"11 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}